Page 11 - Johan Dighed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Karolinska Development’s portfolio company OssDsign raises SEK 270 million through an oversubscribed rights issue Nachrichtenquelle: globenewswire  |  12.05.2021, 13:28  |  41   |  0  STOCKHOLM, SWEDEN – May 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign completed a successful rights issue of shares with preferential rights for the company's existing shareholders to a value of SEK 240 million. T...

(0) STOCKHOLM, SWEDEN - May 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company OssDsign completed a successful rights issue of shares with preferential rights for the company's existing shareholders to a value of SEK 240 million. The rights issue was oversubscribed, to a rate of 185%, and thus the Board of Directors decided to carry out a directed new issue of shares without preferential rights for existing owners through an over-allotment option adding an additional SEK 30 million to the company. Due to the fact that the rights issue was o...

Investegate announcements from Karolinska Development AB (pub, Karolinska Development’s portfolio company OssDsign raises SEK 270 million through an oversubscribed rights issue

(0) STOCKHOLM, SWEDEN - April 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Aprea Therapeutics' drug candidate eprenetapopt for the treatment of acute myeloid leukemia (AML). KDev Investments, a company jointly owned by Karolinska Development and Rosetta Capital, holds 8 percent of the shares in Aprea Therapeutics, which is listed on Nasdaq Global Select Market in the USA. Eprenetapopt is a small molecule targeting the tumor suppressor protein p53. Mutations of the p53 gene oc...

(0) STOCKHOLM, SWEDEN - April 6, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Dilafor has completed the inclusion of patients to its study of tafoxiparin - a drug candidate with the potential to shorten the delivery time in women receiving treatment to initiate labor. About one in four of all pregnant women receive treatment to induce labor, but more than half of these treatments fail. This leads to a prolonged birth process that increases the risk of complications in both the mother and the child. In a previous clinical phase 2a trial, D...